Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

ID DOID:5041
Name esophageal cancer
Definition A gastrointestinal system cancer that is located_in the esophagus.
Source DiseaseOntology.org
Alt Ids DOID:10291 DOID:1104 DOID:1102 DOID:10292 DOID:10448
Path disease disease of cellular proliferation cancer organ system cancer gastrointestinal system cancer esophageal cancer

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
HRAS Q61L IHMT-RAF-128 esophageal cancer sensitive detail...
SMARCA4 mutant PRT3789 esophageal cancer predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01037790 Phase II Palbociclib PHASE II TRIAL OF THE CYCLIN-DEPEDENT KINASE INHIBITOR PD 0332991 IN PATIENTS WITH CANCER Completed USA 0
NCT01128387 Phase Ib/II Fluorouracil Panitumumab Cisplatin Trial of Panitumumab/Cisplatin/Fluorouracil With XRT in Esophageal Cancer Terminated USA 0
NCT01325441 Phase Ib/II Napabucasin + Paclitaxel A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies Completed USA | CAN 0
NCT01366144 Phase I Paclitaxel Veliparib Carboplatin Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction Active, not recruiting USA 0
NCT01522768 Phase II Afatinib + Paclitaxel Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer Completed USA 0
NCT01848756 Phase Ib/II SNX-5422 Safety and Efficacy of SNX-5422 in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Cancers Terminated USA 0
NCT01928290 Phase II Trastuzumab Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer Completed USA 0
NCT02375958 Phase I PCA062 PCA062 in pCAD-positive Tumors. Completed USA | ITA | FRA | ESP 2
NCT02569242 Phase III Docetaxel + Paclitaxel Nivolumab Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer Completed USA | ITA | GBR | DNK | DEU 3
NCT02715531 Phase I Capecitabine Atezolizumab + Cisplatin + Fluorouracil Atezolizumab + Gemcitabine + Nab-paclitaxel Atezolizumab + Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Atezolizumab + Bevacizumab Atezolizumab + Fluorouracil + Leucovorin + Oxaliplatin A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors Completed USA | NZL | AUS 4
NCT02749513 Phase I Itraconazole Itraconazole as a Targeted Therapy for Inhibiting Hedgehog Pathway Signaling in Esophageal Cancer Patients Unknown status USA 0
NCT02960594 Phase I INO-1400 + INO-9012 INO-1400 hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse Completed USA 0
NCT02963831 Phase Ib/II Durvalumab + ONCOS-102 A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Completed USA 0
NCT02970539 Phase I Oraxol + Ramucirumab Ph1b Study of Oraxol in Comb. w. Ramucirumab in Patients w. Gastric, Gastro-esophageal, or Esophageal Cancers Unknown status USA 1
NCT03044613 Phase I Carboplatin + Ipilimumab + Nivolumab + Paclitaxel Carboplatin + Nivolumab + Paclitaxel Nivolumab or Nivolumab/Ipilimumab Prior to Chemoradiation Plus Nivolumab With II/III Gastro/Esophageal Cancer Active, not recruiting USA 0
NCT03126110 Phase Ib/II INCAGN01876 + Ipilimumab + Nivolumab INCAGN01876 + Nivolumab INCAGN01876 + Ipilimumab Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies Completed USA | ESP | BEL | AUS 0
NCT03132922 Phase I afamitresgene autoleucel MAGE-A4c1032T for Multi-Tumor Active, not recruiting USA | CAN 0
NCT03144661 Phase I INCB062079 An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies Terminated USA | BEL 0
NCT03199586 Phase I NP-G2-044 Phase 1 Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Solid Tumors (Including Lymphoma) Completed USA 0
NCT03233724 Phase Ib/II Pembrolizumab Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for, Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas Terminated USA 0
NCT03281369 Phase Ib/II Atezolizumab + Cobimetinib Atezolizumab + Cisplatin + Fluorouracil + Tiragolumab Atezolizumab + Cisplatin + Fluorouracil Atezolizumab + Cobimetinib + Fluorouracil + Leucovorin + Oxaliplatin Atezolizumab + Fluorouracil + Leucovorin + Oxaliplatin Atezolizumab + Linagliptin Atezolizumab + PEGPH20 Atezolizumab + BKT140 Paclitaxel + Ramucirumab Cisplatin + Fluorouracil Fluorouracil + Leucovorin + Oxaliplatin Atezolizumab + Tiragolumab A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer) Active, not recruiting USA | ISR | GBR | ESP | AUS 2
NCT03329950 Phase I CDX-1140 + CDX-301 CDX-1140 A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Solid Tumors Completed USA 0
NCT03330561 Phase I PRS-343 PRS-343 in HER2-Positive Solid Tumors Completed USA 0
NCT03477162 Phase 0 Metformin Metformin Pharmacology in Human Cancers: A Proof of Principle Study Terminated USA 0
NCT03538028 Phase I INCAGN02385 A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies Completed USA 0
NCT03556228 Phase I VMD-928 Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma Recruiting USA 1
NCT03596372 Phase I BAY1834942 Study of BAY1834942 in Patients With Solid Tumors Completed USA | CAN 1
NCT03621982 Phase I Camidanlumab tesirine Study of ADCT-301 in Patients With Selected Advanced Solid Tumors Terminated USA | GBR | BEL 0
NCT03629756 Phase I Etrumadenant + Zimberelimab A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies Completed USA | AUS 0
NCT03700294 Phase I ADCT-601 Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors Terminated USA 0
NCT03720678 Phase I Etrumadenant + Fluorouracil + Leucovorin + Oxaliplatin A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Gastrointestinal (GI) Malignancies Completed USA | AUS 0
NCT03829501 Phase Ib/II Atezolizumab + KY1044 KY1044 Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer Terminated USA | POL | ITA | HUN | GBR 1
NCT03936959 Phase I LY3434172 A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer Completed USA | FRA | BEL | AUS 1
NCT03973333 Phase Ib/II Atezolizumab + IMC-C103C IMC-C103C Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab Withdrawn USA | GBR | ESP 0
NCT04018872 Phase II Itraconazole Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer Recruiting USA 0
NCT04044859 Phase I afamitresgene autoleucel afamitresgene autoleucel + Pembrolizumab afamitresgene autoleucel + Nivolumab ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS) Recruiting USA | ESP | CAN | BEL 0
NCT04068896 Phase I NGM120 Study of NGM120 in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy Completed USA 0
NCT04225117 Phase II Enfortumab vedotin-ejfv A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) Active, not recruiting USA | CAN 1
NCT04250597 Phase I GNX102 Study of GNX102 in Patients With Advanced Solid Tumors Terminated USA 1
NCT04259450 Phase Ib/II AFM24 Study to Assess AFM24 in Advanced Solid Cancers Completed USA | GBR | ESP | DEU 1
NCT04282018 Phase Ib/II BGB-10188 + Zanubrutinib BGB-10188 + Tislelizumab BGB-10188 Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab Completed AUS 1
NCT04287868 Phase Ib/II Bintrafusp alfa + NHS-IL12 + PDS0101 Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies Active, not recruiting USA 0
NCT04336241 Phase I Nivolumab + RP2 RP2 Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors Recruiting GBR | ESP 0
NCT04389632 Phase I SGN-B6A A Study of SGN-B6A in Advanced Solid Tumors Recruiting USA | GBR | FRA | ESP | CHE 1
NCT04419532 Phase I DS-1055a A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors Recruiting USA | CAN 1
NCT04423029 Phase Ib/II DF6002 DF6002 + Nivolumab A Study to Assess DF6002 (BMS-986415) Alone and in Combination With Nivolumab in Participants With Locally Advanced or Metastatic Solid Tumors Recruiting USA | FRA | ESP | AUS 0
NCT04424641 Phase Ib/II GEN1044 A Study on the Safety of GEN1044 (DuoBody-CD3x5T4) in Subjects With Malignant Solid Tumors Terminated USA | ISR | ESP | DNK 0
NCT04430842 Phase I QBS10072S Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S Completed AUS 0
NCT04491942 Phase I Cisplatin + Elimusertib Cisplatin + Elimusertib + Gemcitabine Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer Active, not recruiting USA | CAN 0
NCT04561362 Phase Ib/II BT8009 BT8009 + Pembrolizumab Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies Recruiting USA | ITA | GBR | FRA | ESP | CAN 0
NCT04592653 Phase Ib/II ALKS 4230 ALKS 4230 + Pembrolizumab Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3) (ARTISTRY-3) Active, not recruiting USA | ESP 0
NCT04665921 Phase I SGN-STNV A Study of SGN-STNV in Advanced Solid Tumors Terminated USA | ITA | GBR | FRA | ESP | CAN 0
NCT04772989 Phase I AB308 + Zimberelimab A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies (ARC-12) Active, not recruiting USA | POL | ESP 0
NCT04787042 Phase Ib/II Pembrolizumab + ST-067 ST-067 Obinutuzumab + ST-067 Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 Active, not recruiting USA 0
NCT04837677 Phase I PRT1419 A Study of PRT1419 in Patients With Advanced Solid Tumors Completed USA 0
NCT04914286 Phase Ib/II GFH018 + Toripalimab-tpzi A Study of GFH018 in Combination With Toripalimab in Patients With Advanced Solid Tumors Completed AUS 1
NCT05006794 Phase I GS-9716 + Sacituzumab govitecan-hziy GS-9716 Docetaxel + GS-9716 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies Recruiting USA | ISR 0
NCT05057013 Phase Ib/II HMBD-001 HMBD-001 in Advanced HER3 Positive Solid Tumours Recruiting GBR 0
NCT05069935 Phase I Atezolizumab + FT538 Cetuximab + FT538 FT538 + Trastuzumab FT538 + Pembrolizumab FT538 + Nivolumab Avelumab + FT538 Cyclophosphamide + Fludarabine FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors Terminated USA 0
NCT05076591 Phase I IMM2902 IMM2902, a HER2/SIRPalpha Bispecific mAb-Trap Antibody-receptor Fusion Protein, in Patients With HER2-expressing Advanced Solid Tumors Suspended USA 0
NCT05086692 Phase Ib/II MDNA11 + Pembrolizumab A Beta-only IL-2 ImmunoTherapY Study (ABILITY-1) Recruiting USA | CAN | AUS 1
NCT05306444 Phase I HBM7008 CLN-418 Study on Subjects With Advanced Solid Tumors Completed USA | AUS 0
NCT05358379 Phase Ib/II CYC140 A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma Recruiting USA | ESP 1
NCT05438420 Phase Ib/II Pembrolizumab + Q702 Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors Recruiting USA 1
NCT05500508 Phase Ib/II AMXT1501 + Eflornithine Oral AMXT 1501 Dicaprate in Combination With IV DFMO Active, not recruiting USA | AUS 0
NCT05547321 Phase I OMTX705 + Pembrolizumab OMTX705 Efficacy and Safety Study of OMTX705, Monotherapy and Pembrolizumab-combined, in Subjects With Advanced Solid Tumors. Recruiting USA | ESP 0
NCT05563766 Phase II Itraconazole A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer Not yet recruiting USA 0
NCT05565417 Phase Ib/II IMT-009 Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas Recruiting USA 0
NCT05572684 Phase Ib/II NC410 + Pembrolizumab A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors Recruiting USA 0
NCT05677490 Phase III Fluorouracil + Irinotecan + Leucovorin + Nivolumab + Oxaliplatin Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma Recruiting USA 1
NCT05830097 Phase Ib/II CBP-1019 A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors Recruiting USA 1
NCT05836324 Phase I INCA33890 A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors Recruiting USA | ITA | GBR | FRA | ESP | DNK | CHE 0
NCT05891171 Phase I AB598 + Carboplatin + Pemetrexed Disodium + Zimberelimab AB598 AB598 + Fluorouracil + Leucovorin + Oxaliplatin + Zimberelimab Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers (ARC-25) Recruiting USA | AUS 0
NCT05898828 Phase Ib/II Entinostat + H1299 cell lysate vaccine + Montanide ISA 51 + Nivolumab Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer Withdrawn USA 0
NCT05947474 Phase I ORB-011 ORB-011 In Patients With Advanced Solid Tumors (ORB) Recruiting USA 0
NCT05964361 Phase Ib/II IL15-TransDC First-in-human Interleukin-15-transpresenting Wilms' Tumor Protein 1-targeting Autologous Dendritic Cell Vaccination in Cancer Patients Recruiting BEL 0
NCT05980416 Phase I EO-3021 Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2 Recruiting USA 2
NCT05985083 Phase I IMM47 A Study Of IMM47 In Subjects With Advanced Solid Tumors Recruiting AUS 0
NCT06047379 Phase Ib/II NEO212 NEO212 + Regorafenib Carboplatin + NEO212 + Paclitaxel Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + NEO212 Ipilimumab + NEO212 NEO212 + Pembrolizumab NEO212 + Nivolumab Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis Recruiting USA 0
NCT06238479 Phase I LY4101174 A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors Recruiting USA | ESP | BEL | AUS 1
NCT06242691 Phase II MK-1200 Safety and Efficacy of MK-1200 in Participants With Advanced Solid Tumors Active, not recruiting USA | ISR | AUS 3
NCT06465069 Phase I LY4052031 A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (NEXUS-01) Recruiting USA | GBR | ESP 1
NCT06514651 Phase I MAQ-001 Ipilimumab + MAQ-001 MAQ-001 in Patients With Advanced Solid Tumors Recruiting FRA 0
NCT06597721 Phase I AMT-754 AMT-754 in Patients With Selected Advanced Solid Tumours Not yet recruiting AUS 0